SC
BBIO icon

Savant Capital’s BridgeBio Pharma BBIO Stock Holding History

Savant Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931K Sell
12,479
-1,842
-13% -$129K ﹤0.01% 915
2026
Q1 		$1.06M Buy
14,321
+1,995
+16% +$145K 0.01% 610
2025
Q4 		$943K Buy
+12,326
New +$809K 0.01% 603

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Savant Capital's BBIO Position: Q2 2026 in Review

Savant Capital reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $129K and leaving 12,479 shares worth $931K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Savant Capital first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.06M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Savant Capital held 12,479 shares of BridgeBio Pharma worth $931K as of Q2 2026.
  • Savant Capital sold 1,842 BridgeBio Pharma shares in Q2 2026, an estimated $129K.
  • BridgeBio Pharma made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #915 holding.
  • Savant Capital first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Savant Capital's BridgeBio Pharma position peaked at $1.06M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.